JP2006525341A5 - - Google Patents

Download PDF

Info

Publication number
JP2006525341A5
JP2006525341A5 JP2006513402A JP2006513402A JP2006525341A5 JP 2006525341 A5 JP2006525341 A5 JP 2006525341A5 JP 2006513402 A JP2006513402 A JP 2006513402A JP 2006513402 A JP2006513402 A JP 2006513402A JP 2006525341 A5 JP2006525341 A5 JP 2006525341A5
Authority
JP
Japan
Prior art keywords
treating
complex
composition
tumor sensitive
farnesyltransferase inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006513402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006525341A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/013114 external-priority patent/WO2004098501A2/en
Publication of JP2006525341A publication Critical patent/JP2006525341A/ja
Publication of JP2006525341A5 publication Critical patent/JP2006525341A5/ja
Pending legal-status Critical Current

Links

JP2006513402A 2003-05-02 2004-04-27 ｒａｓ−ファルネシルトランスフェラーゼ阻害剤、シクロデキストリンおよびエタノールの複合体 Pending JP2006525341A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46728703P 2003-05-02 2003-05-02
PCT/US2004/013114 WO2004098501A2 (en) 2003-05-02 2004-04-27 Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011248458A Division JP2012072161A (ja) 2003-05-02 2011-11-14 ｒａｓ−ファルネシルトランスフェラーゼ阻害剤、シクロデキストリンおよびエタノールの複合体

Publications (2)

Publication Number Publication Date
JP2006525341A JP2006525341A (ja) 2006-11-09
JP2006525341A5 true JP2006525341A5 (enExample) 2006-12-21

Family

ID=33435047

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006513402A Pending JP2006525341A (ja) 2003-05-02 2004-04-27 ｒａｓ−ファルネシルトランスフェラーゼ阻害剤、シクロデキストリンおよびエタノールの複合体
JP2011248458A Pending JP2012072161A (ja) 2003-05-02 2011-11-14 ｒａｓ−ファルネシルトランスフェラーゼ阻害剤、シクロデキストリンおよびエタノールの複合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011248458A Pending JP2012072161A (ja) 2003-05-02 2011-11-14 ｒａｓ−ファルネシルトランスフェラーゼ阻害剤、シクロデキストリンおよびエタノールの複合体

Country Status (6)

Country Link
US (1) US7157446B2 (enExample)
EP (1) EP1622628A4 (enExample)
JP (2) JP2006525341A (enExample)
IS (1) IS8102A (enExample)
NO (1) NO20055128L (enExample)
WO (1) WO2004098501A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210145816A1 (en) * 2019-11-15 2021-05-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Pharmaceutical formulation of lonafarnib with a sulfobutylether beta-cyclodextrin

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4371673A (en) 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
HU199444B (en) * 1985-09-10 1990-02-28 Chinoin Gyogyszer Es Vegyeszet Process for producing 7-isopropoxy-isoflavone-cyclodextrene inclusion complex and pharmaceutical compositions therefrom
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
YU45837B (sh) * 1988-01-18 1992-07-20 LEK TOVARNA FARMACEVTSKIH IN KEMIČKIH IZDELKOV d.d. Postopek za pripravo novega inkluzijskega kompleksa nikardipina oz. njegovega hidroklorida z beta-ciklodekstrinom
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1251615B (it) * 1991-10-04 1995-05-17 Golgi Sa Medicamento ad attivita' antielastasica.
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
US5646131A (en) 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
HUT73844A (en) * 1994-11-11 1996-09-30 Chinoin Gyogyszer Es Vegyeszet New taxol complexes and pharmaceutical compositions containing them
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
CZ20012601A3 (cs) * 1999-01-21 2002-05-15 Bristol-Myers Squibb Company Komplex inhibitoru ras-farnesyltranferasy a sulfobutylether-7beta-cyklodextrinu nebo 2-hydroxypropyl-beta-cyklodextrinu a způsob

Similar Documents

Publication Publication Date Title
NO343834B1 (no) Farmasøytisk preparat omfattende en omega-karboksylarylsubstituert difenylurea for behandling av cancer
JP2006524283A5 (enExample)
JP2006503588A5 (enExample)
NO20070753L (no) Fremgangsmåte for fremstilling av dihydropteridinoner
IL191832A0 (en) Pyridiazinone derivatives for the treatment of tumours
DE602006020327D1 (de) 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen
NO20053211D0 (no) Forbindelser for behandling av metabolske forstyrrelser.
NO20076030L (no) Fremgangsmåte for fremstilling av hydroklorsilaner
JP2007520565A5 (enExample)
JP2009536652A5 (enExample)
JP2009519974A5 (enExample)
EP2029172A4 (en) Anti-c35 antibodies for treating cancer
JP2008513426A5 (enExample)
JP2008519810A5 (enExample)
IL188831A0 (en) Compositions for reducing the incidence of drug induced arrhythmia
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.
JP2006525341A5 (enExample)
JP2008513427A5 (enExample)
GB2443588B (en) A pharmaceutical composition useful for the treatment of prostate cancer
FI20040180L (fi) Koostumus psoriasis-taudin hoitamiseksi
EP2009007A4 (en) PLANT-DERIVED THERAPEUTIC AGENT AGAINST MALIGNANT TUMORS
JP2006505577A5 (enExample)
FR2917142B1 (fr) Piece formant noix d'oldham.
ZA200706871B (en) Treatment of metastasized tumors
JP2008143899A5 (enExample)